George A. McCanney, Michael J. Whitehead, Michael A. McGrath, Susan L. Lindsay, Susan C. Barnett
{"title":"神经细胞培养研究脊髓损伤","authors":"George A. McCanney, Michael J. Whitehead, Michael A. McGrath, Susan L. Lindsay, Susan C. Barnett","doi":"10.1016/j.ddmod.2018.10.005","DOIUrl":null,"url":null,"abstract":"<div><p>There are great challenges involved in identifying potential therapies for the repair of spinal cord injury (SCI). It is well accepted that not one, but a combination of therapeutic strategies will be required to effectively repair the damage. However, identifying novel therapeutics is hindered by the lack of reliable methods available that facilitate high throughput screening of numerous compounds. While the use of animals provides an important means for testing new therapies, <em>in vivo</em> models of SCI can be time consuming and require the use of large cohorts of animals. In this review, we have focused on three aspects of repair following SCI (1) neurite outgrowth, (2) glial scar and (3) remyelination. No <em>in vitro</em> model encapsulates all the features of SCI and we discuss the limitations and virtues of the various cultures, which range from individual cell-types through to complex co-cultures. We discuss how these cultures can be used as a moderate throughput screen to identify novel therapeutics for CNS repair before being verified in animal models.</p></div>","PeriodicalId":39774,"journal":{"name":"Drug Discovery Today: Disease Models","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmod.2018.10.005","citationCount":"4","resultStr":"{\"title\":\"Neural cell cultures to study spinal cord injury\",\"authors\":\"George A. McCanney, Michael J. Whitehead, Michael A. McGrath, Susan L. Lindsay, Susan C. Barnett\",\"doi\":\"10.1016/j.ddmod.2018.10.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>There are great challenges involved in identifying potential therapies for the repair of spinal cord injury (SCI). It is well accepted that not one, but a combination of therapeutic strategies will be required to effectively repair the damage. However, identifying novel therapeutics is hindered by the lack of reliable methods available that facilitate high throughput screening of numerous compounds. While the use of animals provides an important means for testing new therapies, <em>in vivo</em> models of SCI can be time consuming and require the use of large cohorts of animals. In this review, we have focused on three aspects of repair following SCI (1) neurite outgrowth, (2) glial scar and (3) remyelination. No <em>in vitro</em> model encapsulates all the features of SCI and we discuss the limitations and virtues of the various cultures, which range from individual cell-types through to complex co-cultures. We discuss how these cultures can be used as a moderate throughput screen to identify novel therapeutics for CNS repair before being verified in animal models.</p></div>\",\"PeriodicalId\":39774,\"journal\":{\"name\":\"Drug Discovery Today: Disease Models\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ddmod.2018.10.005\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today: Disease Models\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1740675718300161\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today: Disease Models","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1740675718300161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
There are great challenges involved in identifying potential therapies for the repair of spinal cord injury (SCI). It is well accepted that not one, but a combination of therapeutic strategies will be required to effectively repair the damage. However, identifying novel therapeutics is hindered by the lack of reliable methods available that facilitate high throughput screening of numerous compounds. While the use of animals provides an important means for testing new therapies, in vivo models of SCI can be time consuming and require the use of large cohorts of animals. In this review, we have focused on three aspects of repair following SCI (1) neurite outgrowth, (2) glial scar and (3) remyelination. No in vitro model encapsulates all the features of SCI and we discuss the limitations and virtues of the various cultures, which range from individual cell-types through to complex co-cultures. We discuss how these cultures can be used as a moderate throughput screen to identify novel therapeutics for CNS repair before being verified in animal models.
期刊介绍:
Drug Discovery Today: Disease Models discusses the non-human experimental models through which inference is drawn regarding the molecular aetiology and pathogenesis of human disease. It provides critical analysis and evaluation of which models can genuinely inform the research community about the direct process of human disease, those which may have value in basic toxicology, and those which are simply designed for effective expression and raw characterisation.